Company news
Anixa Biosciences, Inc. (NASDAQ:ANIX) news
Anixa Biosciences, Inc. news releases on 6ix. Latest, May 21, 2024: Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical…
Press releases — page 3
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
May 20, 2024
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
May 7, 2024
Anixa Biosciences CEO Featured on "Target: Cancer Podcast" by Oncologist Dr. Sanjay Juneja
May 5, 2024
Anixa Biosciences to Participate in the Sidoti Micro-Cap Virtual Conference on May 8 & 9, 2024
April 29, 2024
Anixa Biosciences Welcomes Celebrity Oncologist Dr. Sanjay Juneja to its Cancer Business Advisory Board
April 17, 2024
Anixa Biosciences 2024 Annual Meeting of Stockholders to Include Investor Presentation Open to All Interested Parties
March 13, 2024
Anixa Biosciences Announces Presentation at 24th Annual World Vaccine Congress
March 10, 2024
Anixa Biosciences Initiates Dosing in Second Cohort of Ovarian Cancer CAR-T Clinical Trial
February 11, 2024
Anixa Biosciences Announces Participation in 2024 NeauxCancer Oncology Conference
January 28, 2024
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine Technology
January 22, 2024
Anixa Biosciences to Present at Sidoti Micro-Cap Virtual Conference on January 17, 2024
January 9, 2024
Anixa Biosciences to Present at Biotech Showcase 2024
December 13, 2023
Anixa Biosciences to Host Conference Call This Evening to Discuss Positive New Data from Ongoing Phase 1 Study of Breast Cancer Vaccine
December 5, 2023
Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of Breast Cancer Vaccine
December 5, 2023
Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology
November 26, 2023
Anixa Biosciences to Present at the Ovarian Cancer Research Alliance (OCRA) Ovarian Cancer National Conference
October 30, 2023
Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr. Mark A. Goldberg, to Cancer Business Advisory Board
October 22, 2023
Anixa Biosciences Completes Treatment of First Patient Cohort in Ovarian Cancer CAR-T Clinical Trial
October 12, 2023
Anixa Biosciences Establishes Cancer Business Advisory Board
September 18, 2023
Anixa Biosciences to Participate in September Investor Conferences
August 30, 2023
Anixa Biosciences Announces Treatment of Third Patient in Ovarian Cancer CAR-T Clinical Trial
August 27, 2023
Anixa Biosciences Announces Opening of Enrollment for Keytruda® Arm in Ongoing Breast Cancer Vaccine Clinical Trial
August 6, 2023
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Ovarian Cancer Vaccine Technology
July 26, 2023
Anixa Biosciences Announces Issuance of Canadian Patent for its CAR-T Cancer Therapy Technology
July 10, 2023
Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial
May 21, 2023
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2023 AACR Annual Meeting
March 26, 2023
Anixa Biosciences Announces Notice of Allowance of Additional Key Patent on Breast Cancer Vaccine Technology
February 26, 2023
Anixa Biosciences Announces Formation of Breast Cancer Clinical Advisory Board
February 20, 2023
Anixa Biosciences Announces Maximum Tolerated Dose Reached in Trial of Preventative Breast Cancer Vaccine
December 7, 2022
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the 2022 San Antonio Breast Cancer Symposium
November 7, 2022
Anixa Biosciences Announces Commencement of Phase 1b Trial of its Breast Cancer Vaccine at Cleveland Clinic
October 25, 2022
Anixa Biosciences Announces Presentation on Ovarian Cancer CAR-T Therapy Trial at the Society for Immunotherapy of Cancer (SITC) Annual Meeting
October 9, 2022
Anixa Biosciences Announces Treatment of First Patient in its Ovarian Cancer CAR-T Clinical Trial
August 14, 2022
Anixa Biosciences Announces Notice of Allowance of Additional Patent on Breast Cancer Vaccine Technology
July 20, 2022
Anixa Biosciences Announces Presentation on Breast Cancer Vaccine Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
April 27, 2022
Anixa Biosciences Announces the Initiation of its Ovarian Cancer CAR-T Phase 1 Trial at Moffitt Cancer Center
March 29, 2022
Anixa Biosciences Announces Japanese Patent on Ovarian Cancer Vaccine
January 24, 2022
Anixa Biosciences Announces Patient Dosing of its Investigational Vaccine Candidate in a First-of-its-Kind Preventative Breast Cancer Vaccine Study
October 25, 2021
Anixa Biosciences Announces First Chinese Patent on its CAR-T Cancer Therapy Technology
October 5, 2021
Anixa Biosciences Announces Notice of Allowance for Additional Patent on its CAR-T Cancer Therapy
September 30, 2021
Anixa Biosciences Appoints Dr. Pamela Garzone As Chief Development Officer
September 6, 2021
Anixa Biosciences and Moffitt Cancer Center Announce FDA Clearance to Initiate Clinical Trial of Ovarian Cancer CAR-T Immunotherapy
August 29, 2021
Anixa Biosciences Announces Issuance of U.S. Patent for Ovarian Cancer Vaccine Technology
August 17, 2021
Anixa Biosciences Announces Support from the National Cancer Institute for Ovarian Cancer Vaccine Developed by Cleveland Clinic
May 25, 2021
Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock
March 21, 2021
Anixa Biosciences Announces Issuance and Publication of European Patent for Ovarian Cancer Vaccine Technology
March 11, 2021
Anixa Biosciences Announces European Patent Issued for its CAR-T Cancer Therapy
March 3, 2021
Anixa Biosciences Begins Animal Testing of Covid-19 Therapeutic Candidates
February 15, 2021
Anixa Biosciences and Cleveland Clinic Announce FDA Clearance to Initiate Clinical Trial of Breast Cancer Vaccine
December 20, 2020
Anixa Biosciences Announces Licensing Agreement with Cleveland Clinic for Ovarian Cancer Vaccine Technology
November 30, 2020